Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · USD

$20.2

-0.12 (-0.6%)· Recorded snapshot

Market cap	63.3B
Revenue (ttm)	28.4B
Net income (ttm)	-1B
EPS (ttm)	-$0.33
Shares out	1.6B
P/E (forward)	19.8x
Dividend	$0.49 (2.45%)
Volume	2,594,637
Beta	0.10

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 28.4B
Net income (ttm): -1B
EPS (ttm): -$0.33
P/E (forward): 19.8x
Market cap: 63.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E19.8

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-2.3

P25 n/aP50 n/aP75 n/a

ROIC5.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TAK indicators

Market & fundamental data

Available fields

261

Groups with data

Currency

JPY

Showing 261 of 261 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001395064
Company name	Takeda Pharmaceutical Company Limited
Country	Japan
Country code	US
CUSIP number	874060205
Earnings date	2026-10-29
Earnings time	bmo
Employees	47,029
Employees change	-426
Employees growth	-0.9%
Enterprise value	$95.4B
Exchange	NYSE
Financial currency	JPY
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	March
Founded	1781
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	No
Is SPAC	No
ISIN number	US8740602052
Last 10-K release date	2026-06-17
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$63.3B
Market cap category	Large-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$20.15
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	TAK
Website	https://www.takeda.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	55.53x
Average P/E ratio (3Y)	60.13x
Average P/E ratio (5Y)	42.97x
Earnings yield	-1.62%
EV/EBIT	24.33x
EV/EBITDA	12.46x
EV/FCF	19.62x
EV/Sales	3.37x
FCF / EV yield	5.1%
FCF yield	7.67%
Forward EV/Sales	3.24x
Forward P/E	19.75x
Forward P/S	2.15x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	14.44x
P/(OCF - SBC) ratio	11.45x
P/B ratio	1.37x
P/FCF ratio	13.04x
P/OCF ratio	10.56x
P/S ratio	2.24x
Price/EBITDA ratio	8.28x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	13.85%
EBITDA margin	27.05%
FCF margin	16.71%
Gross margin	64.47%
Operating margin	13.85%
Pretax margin	-2.82%
Profit margin	-3.54%
Profit per employee	$-21,380
Profitable quarters	1
Revenue per employee	$604,230
ROA	2.69%
ROA (5Y)	2.57%
ROCE	4.96%
ROE	-2.26%
ROE (5Y)	2.21%
ROIC	5.13%
ROIC (5Y)	4.47%
SBC / revenue	1.61%
Tax / revenue	0.71%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	-9.83%
EPS growth years	0
FCF growth	-15.29%
FCF growth (Q)	-55.94%
FCF growth (QoQ)	162.06%
FCF growth 3Y	-2.82%
FCF growth 5Y	-3.33%
Gross profit growth	2.29%
Gross profit growth (Q)	12.63%
Gross profit growth 3Y	1.68%
Gross profit growth 5Y	5.05%
Net income growth (Q)	-8.89%
Net income growth years	0
OCF growth	-13.49%
OCF growth (Q)	-40.76%
OCF growth (QoQ)	71.24%
OCF growth 10Y	32.4%
OCF growth 3Y	-1.08%
OCF growth 5Y	-1.57%
Operating income growth	18.13%
Operating income growth (Q)	18.74%
Operating income growth 3Y	0.52%
Operating income growth 5Y	4.2%
Revenue growth	3.1%
Revenue growth (Q)	10.23%
Revenue growth (QoQ)	11.45%
Revenue growth 10Y	9.91%
Revenue growth 3Y	3.94%
Revenue growth 5Y	6.66%
Revenue growth quarters	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.2B
Depreciation and amortization	$3.9B
EBIT	$3.9B
EBITDA	$7.7B
EPS	$-0.33
FCF per share	$3.09
Financing cash flow	$-2.8B
Free cash flow	$4.9B
Free cash flow minus SBC	$4.4B
Gross profit	$18.3B
Income taxes	$202.3M
Investing cash flow	$-2.6B
Net borrowing	$-64.7M
Net cash flow	$682.7M
Net income	$-1B
Operating cash flow minus SBC	$5.6B
Operating income	$3.9B
Revenue	$28.4B
Stock-based compensation	$457.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.09
Book value per share	$29.42
Debt / EBITDA	4.26
Debt / equity	0.73
Debt / FCF	6.98
Goodwill	$37.2B
Interest coverage	3.43
Long-term assets	$76.4B
Long-term liabilities	$32.4B
Net cash (debt)	$-31.2B
Net cash / market cap	-49.06%
Net debt / EBITDA	4.06
Net debt / equity	0.67
Net debt / FCF	6.4
Piotroski F-Score	4
Property, plant and equipment	$13.5B
Shareholders' equity	$46.5B
Tangible book value	$-10.6B
Tangible book value per share	$-6.70
Total assets	$96.4B
Total cash	$2.8B
Total debt	$34.1B
Total liabilities	$49.9B
WACC	4.05%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.31
Current assets	$19.9B
Current liabilities	$17.5B
Current ratio	1.14
Inventory turnover	1.22
Net working capital	$2.7B
Quick ratio	0.51
Working capital	$2.4B
Working capital turnover	0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.64%
Dividend growth	-9.35%
Dividend growth (10Y)	4.94%
Dividend growth (3Y)	-2.03%
Dividend growth (5Y)	-6.81%
Dividend growth years	1
Dividend payment date	2026-07-06
Dividend payment years	8
Dividend payout frequency	Semi-Annual
Dividend per share	$0.49
Dividend yield	2.45%
Ex-dividend date	2026-03-31
FCF payout ratio	15.94%
Last dividend	$0.24
Shareholder yield	4.08%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-11.7%
10Y return CAGR	1.28%
10Y total return	13.58%
150-day SMA	$17.44
15Y price change	-13.82%
15Y return CAGR	0.69%
15Y total return	10.85%
1D price change	-0.59%
1M price change	6.65%
1M total return	6.65%
1W price change	0.17%
1W total return	0.17%
1Y price change	41.96%
1Y return CAGR	41.99%
1Y total return	41.96%
20-day SMA	$19.18
200-day SMA	$17.51
3M price change	15.34%
3M total return	15.34%
3Y price change	49.33%
3Y return CAGR	17.04%
3Y total return	60.34%
50-day SMA	$18.75
50-day SMA vs 200-day SMA	50over200
52-week high	$20.55
52-week high date	2026-10-26
52-week low	$12.99
52-week low date	2025-10-30
5Y price change	45.55%
5Y return CAGR	10.92%
5Y total return	67.88%
6M price change	22.95%
6M total return	22.95%
All-time high	$31.29
All-time high date	2018-02-01
All-time low	$12.28
All-time low date	2022-10-21
Average true range (ATR)	$0.34
Average volume	2.6M
Beta (5Y)	0.1
Change from 52-week high	-1.95%
Change from 52-week low	55.12%
Change from all-time high	-35.71%
Change from all-time low	63.8%
Change from open	1.46%
Day's gap	-2.02%
Dollar volume	$52.3M
High price	$20.22
Low price	$19.86
Monthly RSI	67.26
Open price	$19.86
Position in 52-week range	80.56%
Premarket change	-1.53%
Premarket close	$20.27
Premarket price	$19.96
Premarket volume	9.9K
Previous close	$20.27
Price vs 150-day SMA	15.36%
Price vs 20-day SMA	4.87%
Price vs 200-day SMA	14.9%
Price vs 50-day SMA	7.29%
Relative volume	0.99
RSI	64.87
Sharpe ratio	1.56
Sharpe ratio (3Y)	0.56
Sharpe ratio (5Y)	0.4
Sortino ratio	2.74
Sortino ratio (3Y)	1.08
Sortino ratio (5Y)	0.87
Volume	2.6M
Weekly RSI	69.24
YTD price change	29.03%
YTD total return	29.03%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.6B
Float percentage	100.92%
Shares change (QoQ)	1.56%
Shares change (YoY)	-1.64%
Shares held by insiders	0.12%
Shares held by institutions	50.7%
Shares outstanding	1.6B
Short % of float	0.18%
Short % of shares	0.18%
Short ratio	1.3 days

Deeper analysis on TAK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TAK report

Is a complete TAK research report available?

No complete published report is available for Takeda Pharmaceutical Company Limited (TAK) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Takeda Pharmaceutical Company Limited (TAK)

Price

Financial snapshot

Fair-value bridge

Latest news · TAK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TAK indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TAK

Frequently asked questions